(PDF) Editorial: Tofacitinib and Biologics for

Editorial: Tofacitinib and Biologics for Moderate-To-Severe Ulcerative Colitis-What Is Best in Class?

Alimentary Pharmacology and Therapeutics - United Kingdom

doi 10.1111/apt.14480

Full Text

Abstract

Available in full text

Categories

Gastroenterology

Date

January 17, 2018

Authors

Publisher

Wiley

Related search

Editorial: Tofacitinib and Biologics for Moderate-To-Severe Ulcerative Colitis-What Is Best in Class? Authors’ Reply

Alimentary Pharmacology and Therapeutics

Gastroenterology

English

Efficacy and Safety of Biologic Agents and Tofacitinib in Moderate-To-Severe Ulcerative Colitis: A Systematic Overview of Meta-Analyses

United European Gastroenterology Journal

Gastroenterology

English

EFFICACY AND SAFETY OF TOFACITINIB IN ULCERATIVE COLITIS (Review)

Koloproktologia

English

Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate to Severe Ulcerative Colitis

Gastroenterology

Gastroenterology

English

Safety and Therapeutic Effect of Mesenchymal Stem Cell Infusion on Moderate to Severe Ulcerative Colitis

Experimental and Therapeutic Medicine

Cancer Research

English

A Comparison of Short-Term Therapeutic Efficacy Between Infliximab and Tacrolimus for Moderate to Severe Ulcerative Colitis

Romanian Journal of Internal Medicine

English

Long-Term Outcomes of Cytomegalovirus Reactivation in Patients With Moderate to Severe Ulcerative Colitis: A Multicenter Study

Gastroenterology

English

Editorial: Mesalazine and Mucosal Microbiome in Quiescent Ulcerative Colitis-What Can We Learn?

Alimentary Pharmacology and Therapeutics

Gastroenterology

English

Prognostic Factors Affecting Early Colectomy in Patients With Moderate to Severe Ulcerative Colitis Treated With Calcineurin Inhibitors

Experimental and Therapeutic Medicine

Cancer Research

English